FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen

Today's Daily Dose brings you news about Celgene's MAGNIFY study results; FDA approval of Ipsen's expanded use of Dysport; Genmab getting milestone payment after FDA approves expanded use of Darzalex and encouraging trial results of Xencor's XmAb5871 in patients with active IgG4-Related Disease.

from RTT - Biotech http://ift.tt/2thyRfH
via IFTTT